MBX Biosciences is a preclinical-stage biotech company committed to creating therapies to treat rare endocrine diseases where there is inadequate treatment available.

MBX’s leadership team has collaborated successfully over several decades to discover, develop and commercialize first-in-class endocrine therapeutics. A distinguishing strength of MBX is world-class proprietary peptide drug discovery.

Biotechnology

Education

MBX Biosciences

Kent Hawryluk

Executive Assistant

Vice President, Quality

Michelle Graham

Steven J. Prestrelski

Carolyn Fisher Vanluchene

Matt Gambino

Patricia Carney

Rachel Morrison

Michael A. Dorato

Richard Bartram

Mary Jane Geiger

Directors and Vice Presidents

Leadership Team

Regulatory and Clinical Team

Financial Team

Teams at MBX Biosciences

Directors and Vice Presidents

Leadership Team

Regulatory and Clinical Team

Financial Team